Payment overview · 2025
General Payments
$1,085.26
60 reported records · 12 companies
Healthcare provider profile · identity verified
Dewan Khan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HOPELAWN, NJ · NPI 1306914825
Verified facts
What the public records show
CMS Open Payments records show Dewan Khan, MD received $1,085.26 in general payments during 2025 across 60 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $240.03 | 22.1% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $222.30 | 20.5% | 16 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $146.68 | 13.5% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $100.47 | 9.3% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $92.12 | 8.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $85.72 | 7.9% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $84.93 | 7.8% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.60 | 4.3% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.57 | 1.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.68 | 1.6% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $15.86 | 1.5% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.30 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,085.26 | 60 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $240.03 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $173.87 | 13 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $162.47 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $155.29 | 12 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $76.39 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $70.86 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $69.93 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $69.93 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $67.16 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $48.43 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $46.60 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $29.61 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.57 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 148 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 48 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 124 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
53 | 15 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
31 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
148 | 46 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
124 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 364 | 116 |
| Metformin Hcl | Metformin Hcl | 224 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 204 | 44 |
| Alprazolam | Alprazolam | 190 | 27 |
| Amlodipine Besylate | Amlodipine Besylate | 183 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 165 | 34 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 163 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 159 | 60 |
| Omeprazole | Omeprazole | 149 | 36 |
| Farxiga | Dapagliflozin Propanediol | 148 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 51 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 124 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 121 | 18 |
| Montelukast Sodium | Montelukast Sodium | 120 | 29 |
| Losartan Potassium | Losartan Potassium | 107 | 32 |
| Oxycodone Hcl | Oxycodone Hcl | 83 | suppressed |
| Gabapentin | Gabapentin | 81 | 18 |
| Lisinopril | Lisinopril | 81 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 20 |
| Azithromycin | Azithromycin | 72 | 50 |
| Glipizide | Glipizide | 71 | 18 |
| Tradjenta | Linagliptin | 71 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 22 |
| Alendronate Sodium | Alendronate Sodium | 66 | 19 |
| Simvastatin | Simvastatin | 66 | 22 |
| Famotidine | Famotidine | 64 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 27 |
| Enalapril Maleate | Enalapril Maleate | 60 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 59 | 17 |
| Ezetimibe | Ezetimibe | 57 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 18 |
| Glimepiride | Glimepiride | 55 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 12 |
| Linzess | Linaclotide | 53 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 53 | 19 |
| Carvedilol | Carvedilol | 50 | 12 |
| Jardiance | Empagliflozin | 48 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 34 |
| Eliquis | Apixaban | 45 | 11 |
| Irbesartan | Irbesartan | 45 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 14 |
| Ibuprofen | Ibuprofen | 42 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 41 | suppressed |
| Furosemide | Furosemide | 40 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 29 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 36 | 14 |
| Finasteride | Finasteride | 35 | suppressed |
| Vascepa | Icosapent Ethyl | 35 | suppressed |
| Amoxicillin | Amoxicillin | 34 | 27 |
| Meclizine Hcl | Meclizine Hcl | 33 | 12 |
| Repatha Sureclick | Evolocumab | 33 | suppressed |
| Nabumetone | Nabumetone | 32 | 13 |
| Methylprednisolone | Methylprednisolone | 31 | 24 |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Prolia | Denosumab | 31 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 13 |
| Fenofibrate | Fenofibrate,micronized | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Cilostazol | Cilostazol | 27 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 24 | suppressed |
| Repaglinide | Repaglinide | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 22 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 22 | 11 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 20 | suppressed |
| Terconazole | Terconazole | 20 | 12 |
| Allopurinol | Allopurinol | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 17 |
| Prednisone | Prednisone | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | 11 |
| Atenolol | Atenolol | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Xifaxan | Rifaximin | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,085.26 · 60 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | BREZTRI, Cologuard Collection Kit, FARXIGA, Flector, JARDIANCE, LEQVIO, Licart, MINIMED 780G, MOUNJARO, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Tirosint, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error